Research - San Francisco, California, United States
Digestome Therapeutics is a private biotech company developing first-in-class therapeutics targeting a clinically proven mechanism, VNS (vagus nerve stimulation). VNS has been FDA approved in epilepsy and depression, and is in trials for other psychiatric, neurodegenerative and inflammatory diseases. However, the products are medical devices with limitations (e.g., invasiveness) and are only used as a last resort. Digestome's first-in-class drugs target VNS and have a unique safety profile due to being gut-acting, gut-restricted (no systemic exposure). DGX-001 will enter a first-in-human proof of mechanism study in early 2022.
Gmail
Apache
WordPress.org
Google Tag Manager
Mobile Friendly